---
title: "Lincoln Pharmaceuticals Ltd (LINCOLN) — Share Price, Financials & Analysis"
symbol: "LINCOLN"
company: "Lincoln Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/LINCOLN"
isin: "INE405C01035"
nse_symbol: "LINCOLN"
bse_code: "531633"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 1256.77
generated_at: "2026-09-13T18:25:46.917Z"
---

# Lincoln Pharmaceuticals Ltd (LINCOLN)

Canonical page: https://tapetide.com/stocks/LINCOLN

## Company

- **NSE Symbol:** LINCOLN
- **BSE Code:** 531633
- **ISIN:** INE405C01035
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2004-10-21
- **CEO:** Mr. Mahendrabhai Gulabdas Patel B.A, LLB
- **Employees:** 1853
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** lincolnpharma.com

## About

Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]

## Latest Price

- **Price:** ₹623.5
- **Change:** -9.1 (-1.44%)
- **Open:** ₹635
- **Day High:** ₹635
- **Day Low:** ₹619.1
- **Previous Close:** ₹632.6
- **Volume:** 34328
- **As Of:** 2026-09-11T10:28:08+00:00

## Key Fundamentals

Observed at 2026-09-11T04:37:00.640001Z.

- **Market Cap:** ₹1256.77 Cr
- **Classification:** Microcap
- **P/E (reported):** 13.2
- **P/E (TTM):** 12.95
- **EPS (TTM):** ₹48.16
- **EPS (reported):** ₹48.91
- **Book Value:** ₹378.25
- **Price to Book:** 1.68
- **Dividend Yield:** 0.28%
- **ROE:** 12.26%
- **ROCE:** 16.08%
- **Debt to Equity:** 0.01
- **Revenue (yearly):** ₹671.03 Cr
- **Net Income:** ₹87.87 Cr
- **EBITDA:** ₹97.68 Cr
- **52-Week High:** ₹770
- **52-Week Low:** ₹440
- **RSI (14):** 60.68

## Tapetide Score

- **Score:** 53 / 100
- **Score date:** 2026-09-04
- **Archetype:** Out of Favour
- **What it means:** Financially sound, yet the market is not rewarding it. Cases like this usually need a specific reason the pessimism is misplaced, and patience for that reason to play out.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Falling
- **Percentile:** 61 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 82.44 | 9% |
| growth | 35.94 | 9% |
| momentum | 39.85 | 12% |
| ownership | 17.4 | 24% |
| quality | 62.18 | 22% |
| valuation | 84.93 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.

### Weaknesses

- The company has delivered a poor sales growth of 9.61% over past five years.
- Company has a low return on equity of 13.8% over last 3 years.
- Earnings include an other income of Rs.42.4 Cr.
- Dividend payout has been low at 4.11% of profits over last 3 years
- Working capital days have increased from 159 days to 239 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 47.14% | 136.93% | 34.29% |
| ebitda margin growth | 149.76% | -27.76% | -36.49% | -36.61% |
| net income growth | 212.07% | 6.77% | 7% | 7% |
| revenue growth | 10.05% | 3.92% | 10% | 10% |
| roce | 181.73% | -20.98% | -19.16% | 20.18% |
| roe | 211.52% | -22.11% | 14.17% | -27.84% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| Expenses | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 |
| Operating Profit | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 |
| OPM % | 20 | 20 | 13 | 15 | 18 | 16 | 16 | 15 | 16 | 14 | 13 | 15 |
| Other Income | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Tax % | 25 | 26 | 16 | 20 | 24 | 28 | 29 | 22 | 31 | 18 | 30 | 24 |
| Net Profit | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS in Rs | 13.8 | 14 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | 671 | 694 |
| Expenses | 308 | 299 | 321 | 337 | 376 | 421 | 480 | 522 | 573 | 593 |
| Operating Profit | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 102 | 98 | 101 |
| OPM % | 15 | 18 | 17 | 21 | 20 | 18 | 17 | 16 | 15 | 15 |
| Other Income | 5 | 5 | 11 | 5 | 10 | 22 | 34 | 22 | 33 | 42 |
| Interest | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 | 14 | 15 |
| Profit before tax | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 | 116 | 128 |
| Tax % | 25 | 22 | 23 | 26 | 28 | 27 | 24 | 25 | 24 | — |
| Net Profit | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | 88 | 96 |
| EPS in Rs | 17.31 | 24.36 | 25.72 | 31.12 | 34.63 | 36.4 | 46.58 | 41.11 | 43.88 | 48.16 |
| Dividend Payout % | 9 | 6 | 6 | 5 | 4 | 4 | 4 | 4 | 4 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 | 738 |
| Borrowings | 64 | 61 | 34 | 5 | 1 | 2 | 2 | 1 | 0 | 4 |
| Other Liabilities | 48 | 62 | 63 | 71 | 85 | 99 | 83 | 106 | 125 | 128 |
| Total Liabilities | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 890 |
| Fixed Assets | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 | 191 |
| CWIP | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 | 5 |
| Investments | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 | 209 |
| Other Assets | 186 | 219 | 225 | 232 | 259 | 290 | 339 | 379 | 437 | 486 |
| Total Assets | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 890 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 25 | 27 | 53 | 75 | 69 | 76 | 39 | 63 | 93 | 106 |
| Cash from Investing Activity | -25 | -12 | -18 | -31 | -64 | -78 | -37 | -57 | -79 | -98 |
| Cash from Financing Activity | 0 | -11 | -36 | -38 | -6 | -3 | -4 | -5 | -6 | 0 |
| Net Cash Flow | 0 | 3 | -1 | 7 | -1 | -4 | -2 | 1 | 8 | 8 |
| Free Cash Flow | 7 | 17 | 38 | 68 | 61 | 31 | 26 | 24 | 74 | 82 |
| CFO/OP | 74 | 68 | 104 | 137 | 102 | 104 | 77 | 89 | 117 | 135 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 92 | 111 | 122 | 96 | 98 | 90 | 98 | 102 | 97 | 88 |
| Inventory Days | 63 | 86 | 75 | 95 | 86 | 121 | 106 | 101 | 99 | 94 |
| Days Payable | 54 | 82 | 92 | 102 | 105 | 120 | 77 | 95 | 106 | 100 |
| Cash Conversion Cycle | 100 | 115 | 106 | 88 | 78 | 91 | 126 | 108 | 90 | 82 |
| Working Capital Days | 69 | 89 | 113 | 126 | 119 | 113 | 121 | 121 | 116 | 239 |
| ROCE % | 19 | 19 | 23 | 22 | 25 | 24 | 22 | 22 | 17 | 16 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 50.53% | 49.8% | 49.53% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% |
| FIIs | 2.59% | 3.22% | 3.93% | 3.95% | 5.19% | 5.16% | 5% | 5.14% | 4.72% | 4.7% | 5.19% | 4.6% |
| DIIs | 0% | 0% | 0.05% | 0.04% | 0% | 0% | 0.01% | 0.01% | 0.01% | 0.01% | 1.09% | 0.27% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 37.47% | 37.78% | 37.36% | 37.1% | 36.14% | 36.71% | 36.64% | 36.27% | 36.26% | 36.29% | 34.7% | 36.12% |
| Others | 9.41% | 9.2% | 9.13% | 9.14% | 8.89% | 8.35% | 8.59% | 8.81% | 9.23% | 9.23% | 9.24% | 9.24% |
| No. of Shareholders | 28670 | 29316 | 31375 | 29967 | 31330 | 31848 | 31867 | 31784 | 32370 | 31026 | 28303 | 29396 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 10 / 6 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 624.57 | Sell |
| EMA (10) | 626.34 | Sell |
| SMA (20) | 620.31 | Buy |
| EMA (20) | 620.44 | Buy |
| SMA (50) | 606.58 | Buy |
| EMA (50) | 615.09 | Buy |
| SMA (100) | 627.61 | Sell |
| EMA (100) | 610.62 | Buy |
| SMA (200) | 581.67 | Buy |
| EMA (200) | 597.03 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 53.37 | Neutral |
| MACD (12,26,9) | 6.87 | Buy |
| Stochastic (14,3,3) | 63.4 | Neutral |
| ADX (14) | 31.3 | Buy |
| Williams %R (14) | -54.91 | Neutral |
| ATR (14) | 16.81 | Neutral |
| ROC (12) | 1.79 | Buy |
| Stoch RSI (14) | 27.75 | Neutral |
| UO (7,14,28) | 42.25 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7cae4ed-ade9-4495-a4b6-cad8eb568735.pdf) |
| 2026-09-05 | [Notice Of 32Nd Annual General Meeting Of The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1f99206-48d7-4b99-b320-8b53ff19ab00.pdf) |
| 2026-09-05 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02c6585b-928b-4917-a813-6ae2568ad3b5.pdf) |
| 2026-09-05 | [Update Regarding Dispatch Of Physical Communication To Shareholders To Access Annual Report Of The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a314d54-b529-4c88-9448-0e398c6ee198.pdf) |
| 2026-08-29 | [Corporate Action-Fixes Book Closure For Determining The Dividend If Approved At The AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dcd31b7b-cfa2-480d-bd43-11e80a8a7f47.pdf) |
| 2026-08-29 | [Intimation Of Book Closure And Record Date For The Purpose Of 32Nd Annual General Meeting And Final Dividend For The Financial Year 2025-26.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f90d394-628a-4937-a9c9-06d8853fff09.pdf) |
| 2026-08-26 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ab5a0d7-6956-4ed8-a663-607b0dd7af8d.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=900b4432-7310-4262-abbb-8eb73a81b6b2.pdf) |
| 2026-08-13 | [Board Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter Ended On June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66486fca-fd68-44aa-9212-874deaddc10e.pdf) |
| 2026-08-06 | [Board Meeting Intimation for Board Meeting Intimation For Consideration And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89db39aa-de77-4ae3-8714-52338c20ca14.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Un-Audited Financial Results For Quarter Ended On 30 June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5c8bea6-6180-4fc8-bd7d-00cc19287fdd.pdf) |
| 2026-05-28 | [Audited Financial Results For The Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2298e496-7c98-45fe-9ee1-69e032967937.pdf) |
| 2026-02-12 | [UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56515797-ca90-4745-a79a-b2e953f9a644.pdf) |
| 2025-11-13 | [UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12d9b317-3026-42f6-a947-5951468b0e3a.pdf) |
| 2025-08-07 | [UN AUDITED FINANCIAL RESULTS FOR QUARTER ENDED ON 30-JUNE-2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9938645-4db6-43ff-97e0-ce7b4619dcc8.pdf) |
| 2025-05-22 | [Audited Financial Results For The Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9043464d-4b90-421e-8b38-f8414f6a5599.pdf) |
| 2025-02-13 | [UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58414f1a-44fd-424b-ba32-557aa08b8ba3.pdf) |
| 2024-11-14 | [UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=126956bc-f771-4bd2-b4fa-302a9eca98fa.pdf) |
| 2024-08-08 | [Un-Audited Financial Results For The Quarter Ended 30-June-2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa9c4157-b16a-4ae1-aa07-8883654fa228.pdf) |
| 2024-05-16 | [Audited Financial Results For Quarter And Year Ended 31St March, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9049dd4-85a9-40d1-ab8e-23ef22c27b97.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/08f8b461-6548-4a68-8a3d-f0456f03d61c.pdf) |
| Aug 2016 | [Concall - Aug 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=D6ED85C1_25F5_4FB6_90AB_A9A4F2D660F8_174408.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund)Rules, 2016 and amendments thereof. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 8 May - Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund)Rules, 2016 and amendments thereof.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ef3c55e6-0a7d-46cd-bee4-15d31dc279b6.pdf) |
| 6 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/737dd2c9-a66f-460f-9c8d-f8162c23bf41.pdf) |
| 5 May - Lincoln Pharmaceuticals says it is not a Large Corporate for FY 2025-26. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 5 May - Lincoln Pharmaceuticals says it is not a Large Corporate for FY 2025-26.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/009d7e35-f092-45ae-8222-ebd0a42625c0.pdf) |
| 23 Feb - Listing Obligation and Disclosure Requirements) Regulations, 2015 we attach herewith transcript of conference call held on February 18, 2026. A copy of the same is … | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 23 Feb - Listing Obligation and Disclosure Requirements) Regulations, 2015 we attach herewith transcript of conference call held on February 18, 2026. A copy of the same is …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/37220a84-fb17-42d5-b5fc-85233179b807.pdf) |
| 18 Feb - Conference call audio for results for quarter and nine months ended Dec 31, 2025 posted Feb 18, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 18 Feb - Conference call audio for results for quarter and nine months ended Dec 31, 2025 posted Feb 18, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/de8dc5b2-ad12-4089-8ec9-2f63b8168734.pdf) |
| 16 Apr - Lincoln Pharmaceuticals says it is not a Large Corporate as on 31 March 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 16 Apr - Lincoln Pharmaceuticals says it is not a Large Corporate as on 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6fd043c3-d3b4-41b7-8383-0bd1171599e6.pdf) |
| 13 Feb - Newspaper Advertisement with respect to unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended on December 31, 2025. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Feb - Newspaper Advertisement with respect to unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended on December 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e50ea22a-3602-44a6-93a9-d333fcaa31d3.pdf) |
| 13 Feb - Earnings call Feb 18, 2026 16:00 IST for Q3/9M FY26 results (ended Dec 31, 2025). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Feb - Earnings call Feb 18, 2026 16:00 IST for Q3/9M FY26 results (ended Dec 31, 2025).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/56d6efb8-bbc7-4cec-9c34-236bdcb57d31.pdf) |
| — | [Closure of Trading Window 25 Mar](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4f780d5b-ea9f-4f87-8a2c-38f5320c48bf.pdf) |
| — | [UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2025 12 Feb](https://www.bseindia.com/xml-data/corpfiling/AttachHis/56515797-ca90-4745-a79a-b2e953f9a644.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-02-23 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=37220a84-fb17-42d5-b5fc-85233179b807.pdf) |
| 2024-05-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=08f8b461-6548-4a68-8a3d-f0456f03d61c.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2847bd06-c591-4ab0-bfe8-170272ee6beb.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c67fda9c-8077-4df4-91a4-7af9d3972996.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d7f8d8a3-c85b-47d9-a0d1-f08d8416334d.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/531633/76113531633.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/531633/71810531633.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/531633/66206531633.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/531633/5316330319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/531633/5316330318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/531633/5316330317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/531633/5316330316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:25:46.917Z.